Voyageur Pharmaceuticals Stock Target Price
VM Stock | CAD 0.07 0.01 8.33% |
Voyageur Pharmaceuticals fundamentals help investors to digest information that contributes to Voyageur Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Voyageur Stock. The fundamental analysis module provides a way to measure Voyageur Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Voyageur Pharmaceuticals stock.
Voyageur | Target Price |
Voyageur Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Voyageur Pharmaceuticals from analyzing Voyageur Pharmaceuticals' financial statements. These drivers represent accounts that assess Voyageur Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Voyageur Pharmaceuticals' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 4.3M | 2.8M | 8.5M | 7.5M | 6.8M | 4.0M | |
Enterprise Value | 4.4M | 3.1M | 7.8M | 7.5M | 6.8M | 4.0M |
Voyageur Fundamentals
Return On Equity | -0.85 | ||||
Return On Asset | -0.31 | ||||
Current Valuation | 9.09 M | ||||
Shares Outstanding | 139.47 M | ||||
Shares Owned By Insiders | 10.24 % | ||||
Number Of Shares Shorted | 55.05 K | ||||
Price To Book | 7.27 X | ||||
EBITDA | (1.34 M) | ||||
Net Income | (1.4 M) | ||||
Cash And Equivalents | 27.59 K | ||||
Total Debt | 40 K | ||||
Debt To Equity | 28.10 % | ||||
Current Ratio | 0.16 X | ||||
Book Value Per Share | 0.01 X | ||||
Cash Flow From Operations | (991.25 K) | ||||
Short Ratio | 1.21 X | ||||
Earnings Per Share | (0.01) X | ||||
Target Price | 0.55 | ||||
Beta | 0.32 | ||||
Market Capitalization | 9.07 M | ||||
Total Asset | 2.16 M | ||||
Retained Earnings | (9.13 M) | ||||
Working Capital | (585.25 K) | ||||
Net Asset | 2.16 M |
About Voyageur Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Voyageur Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyageur Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyageur Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Voyageur Stock Analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.